The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting
Abstract
OBJECTIVE: To evaluate the safety and efficacy of aprepitant in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). DATA SOURCES: MEDLINE and PubMed database searches were conducted from 1966 to May 2004 using the following search terms: aprepitant, Emend, substance P, neurokinin-1, chemotherapy, nausea, vomiting, L-754,030, and MK-869. STUDY SELECTION AND DATA EXTRACTION: Large, randomized Phase II and III clinical trials examining the use of aprepitant for CINV, as well as all published drug interaction studies with aprepitant, were included and reviewed. Data lacking in published trials were supplemented with the manufacturer product information. DATA SYNTHESIS: The pharmacokinetics of aprepitant are favorable for once-daily oral dosing. Based on the results of published clinical trials, aprepitant appears to augment the effects of corticosteroids and 5-HT 3 antagonists when given prior to highly emetogenic chemotherapy, including cisplatin. Aprepitant appears to have the most benefit in the prevention of delayed CINV and in preventing emesis rather than nausea. Data in pediatric patients, patients undergoing stem-cell transplantation, and those receiving multiple-day or moderately emetogenic chemotherapy are lacking. Common adverse effects are limited to hiccups, asthenia, and diarrhea. More serious but rare adverse effects include neutropenia. Because aprepitant is a CYP3A4 substrate, a 3A4 inhibitor and inducer, and a 2C9 inducer, close monitoring for drug interactions is warranted. CONCLUSIONS: Triple antiemetic therapy with aprepitant, a corticosteroid, and a 5-HT 3 antagonist appears to provide improved efficacy in the prevention of emesis in patients receiving highly emetogenic chemotherapy. Due to its novel mechanism of action and demonstrated efficacy in this combination, aprepitant should be considered for formulary addition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aprepitant is a relatively new (approved 2003) substance P/neurokinin 1 receptor (NK1) highly selective, high‐affinity antagonist antiemetic agent.”
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
On the receiving end—patient perception of the side-effects of cancer chemotherapy
Coates, A., Abraham, S., Kaye, S. B., Sowerbutts, T., Frewin, C., Fox, R. M., & Tattersall, M. H. N. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90418-2 · Cited by 997
Hesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., de Wit, R., Chawla, S. P., Carides, A. D., Ianus, J., Elmer, M. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.095 · Cited by 779
The distribution of substance P and 5‐hydroxytryptamine in the central nervous system of the dog
Amin, A. H., Crawford, T. B. B., & Gaddum, J. H. (1954) · The Journal of Physiology · doi:10.1113/jphysiol.1954.sp005229 · Cited by 704
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Hesketh, P. J., Kris, M. G., Grunberg, S. M., Beck, T., Hainsworth, J. D., Harker, G., Aapro, M. S., Gandara, D., & Lindley, C. M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.103 · Cited by 605
Poli‐Bigelli, S., Rodrigues‐Pereira, J., Carides, A. D., Julie Ma, G., Eldridge, K., Hipple, A., Evans, J. K., Horgan, K. J., Lawson, F., & On behalf of the Aprepitant Protocol 054 Study Group (2003) · Cancer · doi:10.1002/cncr.11433 · Cited by 564
Gralla, R., Lichinitser, M., Van der Vegt, S., Sleeboom, H., Mezger, J., Peschel, C., Tonini, G., Labianca, R., Macciocchi, A., & Aapro, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg417 · Cited by 467
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
de Boer-Dennert, M., de Wit, R., Schmitz, P., Djontono, J., v Beurden, V, Stoter, G., & Verweij, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.507 · Cited by 378
Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
Navari, R. M., Reinhardt, R. R., Gralla, R. J., Kris, M. G., Hesketh, P. J., Khojasteh, A., Kindler, H., Grote, T. H., Pendergrass, K., Grunberg, S. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400304 · Cited by 370
Research works printed but not linked: 7
- Grunberg SM, 2004, J Support Oncol, 2, 1
- Dibble SL, 2004, Oncol Nurs For, 31, 1
- 10.1002/1097-0142(19931001)72:7<2239::AID-CNCR2820720729>3.0.CO;2-5 · doi:10.1002/1097-0142(19931001)72:7<2239::aid-cncr2820720729>3.0.co;2-5
- 10.1200/jco.2004.22.90140.2094 · doi:10.1200/jco.2004.22.90140.2094
- 2004, 2004 Redbook
- 2003, Product information. Aloxi (palonosetron)
- 10.1200/jco.2004.22.90140.8262 · doi:10.1200/jco.2004.22.90140.8262
Cited by
Aapro, M. S., Grunberg, S. M., Manikhas, G. M., Olivares, G., Suarez, T., Tjulandin, S. A., Bertoli, L. F., Yunus, F., Morrica, B., Lordick, F., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl137 · Cited by 338
“Serotonin antagonists are believed to be effective in acute CINV because serotonin is released rapidly from the enterochromaffin cells in the gastrointestinal tract in the first 24 h [32, 33].”
BackgroundItch: From mechanism to (novel) therapeutic approaches
Yosipovitch, G., Rosen, J. D., & Hashimoto, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.005 · Cited by 343
“The NK-1 inhibitor aprepitant demonstrated efficacy in the treatment of prurigo nodularis, Sezary syndrome, and paraneoplastic itch; however, interactions with other medications restrict its use in some patients.(132,149) In a phase II clinical trial, serlopitant, another NK-1 inhibitor, significantly reduced pruritus…”
BackgroundJordan, K., Gralla, R., Jahn, F., & Molassiotis, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.073 · Cited by 192
Andersson, K.-E., Chapple, C. R., Cardozo, L., Cruz, F., Hashim, H., Michel, M. C., Tannenbaum, C., & Wein, A. J. (2009) · Current Opinion in Urology · doi:10.1097/mou.0b013e32832ce8a4 · Cited by 178
Update and new trends in antiemetic therapy: the continuing need for novel therapies
Feyer, P. C., & Jordan, K. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq600 · Cited by 143
Venkatesan, T., Levinthal, D. J., Tarbell, S. E., Jaradeh, S. S., Hasler, W. L., Issenman, R. M., Adams, K. A., Sarosiek, I., Stave, C. D., Sharaf, R. N., et al. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13604 · Cited by 137
Aprepitant: drug-drug interactions in perspective.
Aapro, M., & Walko, C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq149 · Cited by 126
“Clinical trials of aprepitant with anticancer drugs, including cyclophosphamide, etoposide, taxanes, and vinca alkaloids, failed to produce any clinically significant interaction; however, pharmacokinetic analysis was not always evaluated in the clinical studies [54].”
BackgroundKast, R. E., Karpel‐Massler, G., & Halatsch, M. (2014) · Oncotarget · doi:10.18632/oncotarget.2408 · Cited by 130
Neuromodulatory Processes of the Brain–Gut Axis
Gaman, A., & Kuo, B. (2008) · Neuromodulation Technology at the Neural Interface · doi:10.1111/j.1525-1403.2008.00172.x · Cited by 74
“Tachykinin antagonists have been shown to modulate GI sensations such as nausea with the NK 1 antagonist such as aprepitant (46).”
BackgroundChemotherapy-Induced Nausea and Vomiting
Lohr, L. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31816a0f07 · Cited by 144
Yoshida, M., Masunaga, K., Nagata, T., Yono, M., & Homma, Y. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09r12fm · Cited by 60
Sepúlveda-Vildósola, A. C., Betanzos-Cabrera, Y., Lastiri, G. G., Rivera-Márquez, H., Villasís-Keever, M., del Angel, V. D., Diaz, F., & López-Aguilar, E. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2008.04.007 · Cited by 56
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction
Li, Y.-F., Fu, S., Hu, W., Liu, J.-H., Finkel, K., Gershenson, D., & Kavanagh, J. (2006) · International Journal of Gynecologic Cancer · doi:10.1136/ijgc-00009577-200707000-00001 · Cited by 55
Prospective pharmacologic therapies for the overactive bladder
Andersson, K. (2009) · Therapeutic Advances in Urology · doi:10.1177/1756287209103937 · Cited by 42
“Aprepitant, an NK-1 receptor antagonist used for treatment of chemotherapy-induced nausea and vomiting [Massaro and Lenz 2005], significantly improved symptoms of OAB in postmenopausal women with a history of urgency incontinence or mixed incontinence (with predominantly urgency urinary incontinence), as shown in a we…”
MethodBubalo, J., Cherala, G., McCune, J., Munar, M., Tse, S., & Maziarz, R. (2012) · Journal of clinical pharmacology · doi:10.1177/0091270011398243 · Cited by 41
“Placebo (n = 20) 14/6 0/8/12 46 (19-63) 176 (163-193) 80 (60-108) 1.”
Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting.
Girish, C., & Manikandan, S. (2007) · Indian Journal of Cancer · doi:10.4103/0019-509x.31164 · Cited by 31
Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.
Chan, V., & Yeo, W. (2011) · Breast Cancer · doi:10.2147/bctt.s12955 · Cited by 28
Lee, M. D., Ayanoĝlu, E., & Gong, L. (2006) · Xenobiotica · doi:10.1080/00498250600861785 · Cited by 34
Green, M. S., Green, P., Malayaman, S. N., Hepler, M., Neubert, L., & Horrow, J. C. (2012) · British Journal of Anaesthesia · doi:10.1093/bja/aes233 · Cited by 30
Treatment of Chemotherapy-induced Nausea in Cancer Patients
Ryan, J. L. (2010) · European Oncology & Haematology · doi:10.17925/eoh.2010.06.02.14 · Cited by 33
Medicinal herbs in treating chemotherapy‐induced nausea and vomiting: A review
Rajabalizadeh, R., Rahbardar, M. G., & Hosseinzadeh, H. (2022) · Phytotherapy Research · doi:10.1002/ptr.7563 · Cited by 25
“Also, shogaols and gingerols are weak NK-1 receptor antagonists (Abdel-Aziz, Windeck, Ploch, & Verspohl, 2006) and prevent neurons from forming efferent signals of CTZ to lower parts (Massaro & Lenz, 2005).”
BackgroundChoi, M., Jiles, C., & Seibel, N. (2010) · Journal of pediatric hematology/oncology · doi:10.1097/mph.0b013e3181e5e1af · Cited by 24
“Aprepitant targets substance P, a tachykinin that plays a central role in the pathophysiology of CINV, which in turn mediates its action through NK-1.(5) Aprepitant has been shown to be effective in the prevention of CINV(6) and in the improvement of DNV in adults.”
BackgroundKaushal, P., Atri, R., Soni, A., & Kaushal, V. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.567 · Cited by 20
“It has shown promising results in controlling both phases of CINV [22, 23].”
BackgroundPharmacologic Management of Lower Urinary Tract Storage and Emptying Failure
Andersson, K., & Wein, A. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00068-2 · Cited by 12
Hsu, Y.-C., Chen, C., Tam, K.-W., & Hsu, C.-Y. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03157-2 · Cited by 18
“Clinical trials have shown that NK1RA improves the antiemetic effects of 5-HT3RAs and corticosteroids [45], and a recent meta-analysis demonstrated its clinical benefits, which showed that NK1RAs in combination with a 5-HT3RA plus a glucocorticoid can provide improved CINV protection [46].”
BackgroundAnticipatory nausea in animal models: a review of potential novel therapeutic treatments
Rock, E. M., Limebeer, C. L., & Parker, L. A. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-3942-9 · Cited by 20
“…Tsukuda et al. 2009; villalon and Chan 2004) NK-1 receptor antagonists Alone Delayed emesis (not acute, Cocquyt et al. 2001) and less so for nausea (Massaro and Lenz 2005) Not evaluated Not evaluated et al. 1979; Frytak et al. 1979; Kluin-Neleman et al. 1979; Lucas and Laszlo 1980; McCabe et al.…”
BackgroundBoccia, L., Borner, T., Ghidewon, M. Y., Kulka, P., Piffaretti, C., Doebley, S. A., Jonghe, B. C. D., Grill, H. J., Lutz, T. A., & Foll, C. L. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101444 · Cited by 18
“Aprepitant [62,63,64,65,66], has been developed and successfully employed to mitigate nausea and emesis in different medical fields (e.”
BackgroundLee, J., Dibble, S., Dodd, M., Abrams, D., & Burns, B. (2010) · Oncology Nursing Forum · doi:10.1188/10.onf.e419-e425 · Cited by 14
“he American Cancer Society (2010) estimated that 1,529,560 new cases of cancer will be diagnosed in 2010 and 80% will be treated with chemotherapy (Massaro & Lenz, 2005).”
BackgroundRecent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting
Bhandari, P. (2012) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.104710 · Cited by 13
Balancing immunotherapy and corticosteroids in cancer treatment: dilemma or paradox?
Ottaiano, A., Santorsola, M., Capuozzo, M., & Scala, S. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf045 · Cited by 13
“27 The effectiveness of NEPA (netupitant–palonosetron)-based regimens to aprepitant-based regimens was evaluated in managing CINV, finding NEPA-based therapies more effective in preventing CINV, especially during the delayed and overall phases following chemotherapy.”
Current and emerging systemic treatments targeting the neural system for chronic pruritus
Golpanian, R. S., & Yosipovitch, G. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1775815 · Cited by 13
Ibrahim, R. B., Abidi, M., Ayash, L., Cronin, S., Cadotte, C., Mulawa, J., Jacobson, P., Smith, D., Uberti, J., & Edwards, D. (2008) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155208089846 · Cited by 9
Update on the Management of Chemotherapy‐induced Nausea and Vomiting
Viale, P. (2006) · Journal of Infusion Nursing · doi:10.1097/00129804-200609000-00007 · Cited by 9
Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
Yang, M.-J., Xu, H.-R., Li, H., Chen, W.-L., Yuan, F., & Li, X.-N. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s243924 · Cited by 8
Ioroi, T., Furukawa, J., Kume, M., Hirata, S., Utsubo, Y., Mizuta, N., Miyake, H., Fujisawa, M., & Hirai, M. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3967-2 · Cited by 8
Highly effective use of aprepitant in an adolescent girl with severe cyclic vomiting syndrome
Nivatsi, M., Aslanidou, I., & Mantadakis, E. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-241132 · Cited by 6
Nasu, R., Nannya, Y., & Kurokawa, M. (2015) · International journal of hematology · doi:10.1007/s12185-015-1735-y · Cited by 6
“The adverse effects of aprepitant include hiccups, asthenia, and diarrhea, and rare but serious events include neutropenia [32].”
BackgroundLarusso, J., Waldman, S., & Kraft, W. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.1.27 · Cited by 5
Frontiers in functional dyspepsia
Fajardo, N. R., Cremonini, F., & Talley, N. J. (2005) · Current Gastroenterology Reports · doi:10.1007/s11894-005-0021-1 · Cited by 5
“Aprepitant (NK1 antagonist) is used in chemotherapy-induced emesis [86,87] and has not been tested in FD, although the localization of NK1 receptors on gastrointestinal vagal afferents and on the brain nucleus tractus solitarii [ 88 ] suggests a potential use of this drug for the symptoms of nausea and vomiting in sev…”
BackgroundSymptom Management in Children with Cancer
Ullrich, C., Berde, C. B., & Billett, A. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00031-5 · Cited by 13
Cyclic vomiting syndrome: From pathophysiology to treatment
Jiménez‐Castillo, R. A., Frazier, R., Venkatesan, T., & Remes-Troche, J. M. (2024) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2024.06.001 · Cited by 4
Long, J. B., Galdi, L., Hentz, J., Leslie, J., Magtibay, P., Kho, R., Cornella, J., & Magrina, J. (2014) · doi:10.4236/ojanes.2014.412043 · Cited by 4
Xu, L., Ma, B., Yu, S., Xia, C., & Wu, J.-T. (2014) · Bioanalysis · doi:10.4155/bio.14.228 · Cited by 3
Chemotherapy induced nausea & vomiting CINV
Nandeesh, B., & Reddy, T. (2012) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp002512 · Cited by 4
Physiology and Pharmacology of the Bladder
Andersson, K. (2011) · Springer eBooks · doi:10.1007/978-1-84882-034-0_9 · Cited by 1
Bladder Pharmacology and Treatment of Lower Urinary Tract Symptoms: Recent Advances
Andersson, K., & Gratzke, C. (2008) · doi:10.3834/uij.1939-4810.2008.07.06 · Cited by 2
“Aprepitant, an NK-1 receptor antagonist used for treatment of chemotherapy-induced nausea and vomiting [117] significantly improved symptoms of OAB in postmenopausal women with a history of urgency incontinence or mixed incontinence (with predominantly urgency urinary incontinence), as shown in a well designed pilot R…”
MethodHuang, A., Jiang, Z., Liang, Z., 汤纳平, Liu, J., Yu, X., Wang, B., & Wang, X. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s602693 · Cited by 1
Current Pharmacologic Treatment of Lower Urinary Tract Symptoms
Andersson, K. (2014) · Current clinical urology · doi:10.1007/978-1-4939-0853-0_13 · Cited by 1
Efficacy of Olanzapine against Nausea and Vomiting in Cancer Patients Receiving Chemotherapy
Sakata, Y., Hiraki, K., Uetake, N., Miyamori, S., Yonezawa, U., Chie, H.-M., Iwamoto, Y., Noda, M., Kitaguchi, S., Sumiyoshi, H., et al. (2010) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.36.717 · Cited by 1
Chemotherapy-induced Nausea and Vomiting
Nevadunsky, N. S., & Matulonis, U. A. (2009) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2009.05.1.10 · Cited by 1
“The areas under the curve of oral dexamethasone and intravenous methylprednisolone have been shown to be increased with use of aprepitant, and steroid doses should be reduced.(45)”
BackgroundLevinthal, D. J., Killian, B., & Issenman, R. M. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14901 · Cited by 1
Síndrome de vómitos cíclicos: de la fisiopatología al tratamiento
Jiménez‐Castillo, R. A., Frazier, R., Venkatesan, T., & Remes-Troche, J. M. (2024) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2024.06.001 · Cited by 1
Mora, R. M., & Corredoira, V. H. (2005) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(05)71267-6
Antiemetic therapy in cancer: an update
Horiot, J.-C. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.10.1713
“In addition, further improvements in the antiemetic control of vomiting (particularly in the delayed phase) in patients receiving highly emetogenic chemotherapy, including cisplatin, have been demonstrated with the addition of the NK1-receptor antagonist, aprepitant, to the combination of a 5-HT3-receptor antagonist a…”
BackgroundUSEFULNESS OF ANTI-EMETICS IN THE TREATMENT OF CANCER: A REVIEW
Simon, P., Jayachandran, M., Vijendra, R., Rao, S., Baliga, M., & Palatty, P. (2021) · doi:10.35503/ijmlr.2021.6205
“The significance of the interaction between substance P and its receptor Neurokinin 1 (NK1) in CINV is becoming clearer with more studies being done([35]).”
Background
Metadata
- Authors
- Massaro, A. M., & Lenz, K. L.
- Affiliations
- Medical University of South Carolina (US)
- Corresponding author
- Lenz, Kristi L
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2005-01
- Volume
- 39
- Issue
- 1
- Pages
- 77-85
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2163903618
- Cited by
- 73
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2015: 2 · 2014: 5 · 2013: 2 · 2012: 4
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- aprepitant, chemotherapy-induced nausea and vomiting, antiemetic therapy, highly emetogenic chemotherapy, cisplatin, substance P, NK1 receptor antagonists, pharmacokinetics, drug interactions, CYP3A4, corticosteroids, 5-HT3 receptor antagonists, adverse effects, neutropenia, drug formulary
- MeSH terms
- Aprepitant, Antiemetics, Antineoplastic Agents, Drug Interactions, Humans, Morpholines, Nausea, Patient Education as Topic, Vomiting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.